Name | Palonosetron hydrochloride |
Description | Palonosetron hydrochloride (RS 25259) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting. |
In vivo | Palonosetron exhibits a longer plasma half-life of approximately 40 hours compared to other antagonists in its class (ondansetron, 4 hours; tropisetron, 7.3 hours; dolasetron, 7.5 hours; ranisetron, 8.9 hours). Additionally, it demonstrates a hundredfold greater binding affinity to the 5-HT3 receptor, with a pKi of 10.5, which is significantly higher than that of granisetron (pKi 8.91), tropisetron (pKi 8.81), ondansetron (pKi 8.39), and dolasetron (pKi 7.6). |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 100 mg/mL (300.42 mM), Sonication is recommended. DMSO : 3.33 mg/mL (10.00 mM), Sonication is recommended.
|
Keywords | Serotonin Receptor | RS-25259 | Inhibitor | inhibit | 5-HT Receptor | Palonosetron hydrochloride | Palonosetron | 5-hydroxytryptamine Receptor | Palonosetron Hydrochloride | RS25259 |
Inhibitors Related | Alverine citrate | Olanzapine | Dapoxetine hydrochloride | CLOZAPINE N-OXIDE | Amitriptyline hydrochloride | Cloperastine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | GPCR Compound Library | Anti-Cancer Drug Library |